ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525181-22-00

Enrollment

Registered

2026-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Brief summary

presence of prostate cancer recurrence at 1-year follow-up detected by PSMA PET and confirmed by biopsies (gold standard).The sensitivity and specificity of PSMA PET will be estimated, as well as the positive predictive values.

Detailed description

presence of prostate cancer recurrence at 1-year follow-up detected by multiparametric MRI and confirmed by biopsies (gold standard), PSMA PET FALSE NEGATIVE RATE AT THE TIME OF DIAGNOSIS, ESTIMATION OF THE DIAGNOSTIC PERFORMANCE OF THE PRIMARY SCORE

Interventions

DRUGPIFLUFOLASTAT (18F)

Eligibility

Sex/Gender

Male

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
presence of prostate cancer recurrence at 1-year follow-up detected by PSMA PET and confirmed by biopsies (gold standard).The sensitivity and specificity of PSMA PET will be estimated, as well as the positive predictive values.	—

Secondary

Measure	Time frame
presence of prostate cancer recurrence at 1-year follow-up detected by multiparametric MRI and confirmed by biopsies (gold standard), PSMA PET FALSE NEGATIVE RATE AT THE TIME OF DIAGNOSIS, ESTIMATION OF THE DIAGNOSTIC PERFORMANCE OF THE PRIMARY SCORE	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 26, 2026